Justice Dept Tweaks Crime Victim Feedback Forms Online
Published Date: 2/18/2026
Notice
Summary
The Department of Justice wants to bring back and update a feedback form used by the Office for Victims of Crime Training and Technical Assistance Center. This change aims to make it easier and quicker for people to share their thoughts, using more electronic options. Anyone who uses or benefits from OVC TTAC services can comment until April 20, 2026, helping shape how the form works without adding extra hassle or cost.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-15458, Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority
This notice of proposed rulemaking ("NPRM") would implement a provision of the Immigration and Nationality Act ("INA" or "the Act") that authorizes Immigration Judges, under regulations prescribed by the Attorney General, to sanction by civil money penalty any action (or inaction) in contempt of the proper exercise of their authority by certain individuals. The rule would: define the scope of the contempt authority; provide procedures for contempt findings, penalty determinations, and penalty payment; establish an appellate process; and implement oversight of the use of contempt authority. The rule would also make conforming changes to the grounds for practitioner discipline.
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-09160, Implementing PATRIOT Act Improvements: Contraband Cigarettes and Smokeless Tobacco
Starting June 8, 2026, new rules crack down harder on illegal cigarette and smokeless tobacco sales. The government lowered the amount that counts as smuggling from 60,000 to just 10,000 cigarettes and now includes smokeless tobacco in the crackdown. Sellers and distributors must keep better records and report more info, making it tougher to dodge the law and protect honest businesses.
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
2026-16775, Notice of Lodging of Proposed Consent Decree Under the Clean Water Act
Previous / Next Documents
Previous: 2026-03211, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZEVASKYN (Prademagene Zamikeracel)
The FDA just gave a special priority review voucher to Abeona Therapeutics for their rare pediatric disease treatment, ZEVASKYN, approved in April 2025. This voucher speeds up future drug reviews, helping get important medicines to patients faster. It’s a big win for kids with rare diseases and could save time and money in bringing new treatments to market.
Next: 2026-03213, Determination That TOLECTIN DS (Tolmetin Sodium) Capsule, Equivalent to 400 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOLECTIN DS (tolmetin sodium) 400 mg capsules weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back!